Clinical Evaluation of a Multifocal Contact Lens on Symptomatic Patients
This study has been completed.
Sponsor:
Vistakon
Collaborator:
Visioncare Research Ltd.
Information provided by:
Vistakon
ClinicalTrials.gov Identifier:
NCT01016652
First received: November 18, 2009
Last updated: January 21, 2010
Last verified: January 2010
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study is to evaluate the effect of a multi-focal contact lens on symptomatic patients.
| Condition | Intervention |
|---|---|
|
Presbyopia |
Device: Etafilcon A Multifocal Contact Lens Device: Etafilcon A Contact Lens |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Intervention Model: Crossover Assignment Masking: Double Blind (Subject, Investigator) Primary Purpose: Treatment |
Resource links provided by NLM:
Further study details as provided by Vistakon:
Primary Outcome Measures:
- Subjective Vision [ Time Frame: After two weeks ] [ Designated as safety issue: No ]
Secondary Outcome Measures:
- Amplitude of Accommodation [ Time Frame: After two weeks ] [ Designated as safety issue: No ]
| Enrollment: | 51 |
| Study Start Date: | October 2009 |
| Study Completion Date: | January 2010 |
| Primary Completion Date: | January 2010 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
| Experimental: Etafilcon A Multifocal |
Device: Etafilcon A Multifocal Contact Lens
Comparison of 2 soft contact lens designs.
|
| Active Comparator: Etafilicon A |
Device: Etafilcon A Contact Lens
Comparison of 2 soft contact lens designs.
|
Eligibility| Ages Eligible for Study: | 35 Years to 47 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- To have signed an informed consent form (documented by the investigator in the Case Report Form [CRF]).
- Be existing daily wear spherical single-vision soft CL wearers (no extended wear in the last 3 months, but silicone hydrogels in daily wear are allowed).
- Between 35 and 47 years of age (inclusive).
- Have a CL spherical distance requirement between -1.00D and -6.00D (-6.50D refractive) in both eyes.
- Refractive astigmatism of 0.75D or less in both eyes.
- Visual symptoms associated with near vision
- Be correctable to a visual acuity of 6/9 (20/30) or better in each eye.
Have normal eyes with no evidence of abnormality or disease. For the purpose of this study a normal eye is defined as one having:
- No amblyopia.
- No evidence of lid abnormality or infection.
- No conjunctival abnormality or infection.
- No clinically significant slit lamp findings (i.e. stromal haze, staining, scarring, Vascularization, infiltrates or abnormal opacities).
- No other active ocular disease.
Exclusion Criteria:
- Monovision user or multifocal CL wearer.
- Regular user of reading spectacles (i.e. daily usage).
- Requires concurrent ocular medication.
- Clinically significant (Grade 3 or 4) corneal stromal haze, corneal Vascularization, tarsal abnormalities, bulbar hyperemia, limbal hyperemia, or any other abnormality of the cornea that would contraindicate CL wear.
- Corneal staining Grade 3 in more than two regions.
- Has had any anterior ocular surgery. Has had any other ocular surgery or injury within 8 weeks immediately prior to enrollment for this study.
- Pre-existing ocular irritation that would preclude CL fitting.
- Keratoconus or other corneal irregularity.
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01016652
Locations
| United States, Arkansas | |
| North Little Rock, Arkansas, United States | |
| United States, Missouri | |
| Blue Springs, Missouri, United States | |
| Lake Ozark, Missouri, United States | |
| United States, Ohio | |
| Warren, Ohio, United States | |
| United States, Pennsylvania | |
| Kittanning, Pennsylvania, United States | |
| United States, Rhode Island | |
| Warwick, Rhode Island, United States | |
| United States, South Dakota | |
| Chamberlain, South Dakota, United States | |
| United States, Vermont | |
| Burlington, Vermont, United States | |
Sponsors and Collaborators
Vistakon
Visioncare Research Ltd.
More Information
No publications provided
| Responsible Party: | Tom Karkkainen, Johnson & Johnson Vision Care, Inc. |
| ClinicalTrials.gov Identifier: | NCT01016652 History of Changes |
| Other Study ID Numbers: | CR-4558, VMFL-511 |
| Study First Received: | November 18, 2009 |
| Last Updated: | January 21, 2010 |
| Health Authority: | United States: Institutional Review Board |
Additional relevant MeSH terms:
|
Presbyopia Refractive Errors Eye Diseases |
ClinicalTrials.gov processed this record on May 19, 2013